Emad Shash

Procedures performed: 

SCIENTIFIC AREAS OF INTEREST

Breast Cancer, Genito-Urinary Oncology, Gynecologic Oncology, Thoracic Oncology, Gastro- intestinal Oncology, Rare Cancers, Medical Education, Clinical trials methodology, Medical & Hemato-Oncology

Assessment, Diagnosis and treatment planning including 

Chemotherapy, Targeted and immunotherapy 

• Breast Cancer
• Genito-Urinary Oncology
• Gynecologic Oncology
• Thoracic Oncology
• Gastrointestinal Oncology
• Rare Cancers
• Medical & Hemato-Oncology

Qualifications

1998-2004: M.B.B.Ch, Kasr El-Aini Faculty of Medicine   Cairo University, Cairo, Egypt     

2010:  Master Degree: Medical oncology, National Cancer Institute, Cairo University, Cairo

2015:  Doctorate of Medical Oncology & Hemato-Oncology, The National Cancer Institute, Cairo University, Cairo, Egypt

2015: Certification of Excellence in fundamentals of Clinical Trials Methodology, European Organization for Research and Treatment of Cancer, Brussels, Belgium

2017:   Diploma of Hospital Quality Management & Patient Safety Joint Commission International, 57357 CHE Academy, Cairo.

Membership

• Fellow at the Cancer Fertility preservation unit of the European Institute of Oncology, Milan, Italy.
• European Society of Gynecologic Oncology (ESGO).
• American Society of Clinical Oncology (ASCO). Multidisciplinary Course Management Course member of the international affairs committee.
• European Association of Cancer Education (EACE).
• European Society of Medical Oncology (ESMO), Panel Voting member.
• Scientific board member of the European Clinical Research Infrastructure (ECRIN).
• National Advisory Board member in Ain-shams Medical Students Research Association (AMSRA).
• Scientific board & founding member of C.A.I.R.O journal club, oncology educational forum, Cairo, Egypt.

SHORT BIOGRAPHY

Dr. Emad Shash, M.B.B. Ch, MSc, M.D., is an esteemed Medical Oncologist and a leader in the field of breast cancer care and clinical research. He currently serves as the Medical Director and General Manager of the Breast Comprehensive Cancer Hospital at the National Cancer Institute, Cairo University. Since 2016, Dr. Shash has also been the Head of the Medical Oncology Department and Breast Cancer Program Director at Shifaa Al Orman Cancer Hospital, Luxor, Egypt.

Dr. Shash earned his medical degree from the Faculty of Medicine, Cairo University, in 2004 and specialized in Medical Oncology at the National Cancer Institute, Cairo University, in 2009. Between 2011 and 2015, he was the coordinating research physician and medical lead for the Breast, Gynecologic Oncology, and Genito-Urinary Oncology groups at the European Organization for Research and Treatment of Cancer (EORTC), based in Brussels, Belgium. During this time, Dr. Shash played a pivotal role in the development, conduct, and publication of EORTC clinical trials (Phases I, II, and III), contributing to budget and resource planning and guiding the scientific strategy of the EORTC groups. His efforts were recognized with an "Excellence in Fundamentals of Clinical Trials Methodology" award.

In addition to his clinical and research contributions, Dr. Shash is deeply committed to cancer education, playing an active role in training medical students, nursing staff, and junior oncologists both regionally and internationally. He is the co-founder of the Egyptian Medical Sciences Foundation and has published numerous well-recognized review and original articles in prestigious national and international journals.

Dr. Shash is a peer reviewer and specialty editor for several leading international scientific journals. He is also an active member of multiple professional societies, including the European Society of Medical Oncology (ESMO), where he serves as a panel member, the European Association of Cancer Education (EACE), the American Society of Clinical Oncology (ASCO), where he contributes to the International Affairs Committee, and the Arab Medical Association against Cancer (AMAAC). His extensive experience and dedication to both clinical care and education make him a respected figure in the global oncology community.

• 2006 - 2010: Resident - Department of Medical Oncology - The National Cancer Institute - Cairo University
• 2010 - 2012: Medical Oncology Course Instructor and Consultant, National Cancer Institute, Cairo University, Nursing Technical Institute, Cairo
• 2010 - 2012: Education and E-Learning Development Instructor and Consultant, National Cancer Institute, Cairo University, Cairo
• 2011 - 2012: Associate Director for Junior Medical Staff training and Development, National Cancer Institute, Cairo University, Cairo
• 2012 - 2015: Clinical Research Physician & Medical Lead, European Organization for Research & Treatment of Cancer, Medical Department, Brussels, Belgium
• 2010 – present: Staff Member, National Cancer Institute, Cairo University, Medical Oncology Department, Cairo, Egypt
• 2004 – present:  Medical Oncologist & Consultant Oncology clinic Private Centre, Cairo, Egypt
• 2015 – present: Clinical Research Development Consultant
• 2016 – present: Quality control coordinator for Postgraduate studies and educational development consultant for Masters & Doctorate degrees of the Medical Oncology & Malignant Hematology, NCI, Cairo University, Egypt
• 2016 – present: Visiting Consultant of Medical Oncology at Shifaa Al-Orman Hospital, Luxor, Egypt
• 2016 – present: Deputy Medical Director at National Cancer Institute, Cairo University, Cairo, Egypt
• 2017-2021: Associate Editor of the Journal of Egyptian National Cancer Institute (JENCI)
• 2018 – present: Scientific Advisor for Her Excellence Egyptian Minster of Health & Population. National Program for upgrade and accreditation of the Egyptian Governmental Hospitals, Egypt

Other Experience and Professional Memberships

2015 – Present Scientific board & founding member of C.A.I.R.O journal club, oncology educational forum, Cairo, Egypt

2016 – Present National Advisory Board member in Ain-shams Medical Students Research Association (AMSRA)

2014- Present Scientific board member of the European Clinical Research Infrastructure (ECRIN)

2008- Present European Society of Medical Oncology (ESMO), Panel Voting member

2010 - Present European Association of Cancer Education (EACE)

2012 - Present American Society of Clinical Oncology (ASCO). Multidisciplinary Course

Management Course member of the international affairs committee

2013 - Present European Society of Gynecologic Oncology (ESGO)

2010 Fellow at the Cancer Fertility preservation unit of the European Institute of Oncology, Milan, Italy

CLINICAL TRIALS PARTICIPATION

• Dr Shash had participated in over 70 international Oncology clinical trials (in different phases of development) since 2008.

• Dr Shash had executed different roles (Study coordinator, Sub-investigator, Principal investigator & Sponsor Medical Monitor)

• 2015-Ongoing (NCI, Cairo University Involvement & SOH Involvement): Lead and expand a robust portfolio of international, industry-sponsored and investigator-initiated clinical trials in breast and women’s cancers (and selected solid tumors). Serve as Principal Investigator (site; national on selected studies), with responsibilities spanning feasibility and contracting, IRB/ethics submissions, site activation, team training, SOP development, eCRF oversight and data quality, pharmacovigilance/SAE reporting, monitoring and audit readiness, and GCP/ICH-E6 compliance. Collaborate with global sponsors and partners (e.g., AstraZeneca, Novartis, Pfizer, Roche) and academic networks to deliver Phase II–III programs, while designing IITs focused on patient navigation, supportive care, digital oncology, and health-systems improvement relevant to LMIC settings. Established multidisciplinary research operations across NCI and SOH, accelerated equitable enrolment, and translated trial findings into practice change, patient education, and peer-reviewed outputs.

• 2012-2015 (EORTC involvement): Participated in design, development, and 

protocol/amendment writing for multiple EORTC-led and collaborating international studies across gynecologic oncology, breast, GI, lung, head & neck, and lymphoma—examples include 55102/55112 (endometrial), 55116 (uterine leiomyosarcoma), 1212 (clear-cell ovary/endometrium), 62113 (HGUS; cabozantinib maintenance), 55994 (locally advanced cervical cancer), 20101 (PETadapted Hodgkin), 22114 (TOP GEAR—preoperative therapy in resectable gastric/EGJ), 22085 (DCIS fractionation), 1219 (DAHANCA-29, hypoxia-guided HNSCC), 22113 (LungTech SBRT), 21081 (lenalidomide maintenance in advanced CTCL), and 55092 (pazopanib + paclitaxel/carboplatin in platinum-resistant ovarian). In parallel, contributed to medical safety monitoring, data review, and interim/final analyses with EORTC HQ and lead investigators for key trials, including 22991 (prostate RT ± hormonal therapy), 21011 (bexarotene + PUVA in mycosis fungoides), 20051 (H10 PET-adapted early Hodgkin), 20012 (BEACOPP vs ABVD in advanced Hodgkin), as well as 55092, 55994, 21081, and 22042 (adjuvant postoperative high-dose RT for atypical/malignant meningioma), supporting publications and evidence translation.

Journal publications (chronological)

1. 2025

o Abdelwhab, Z., Elshwey, R., Adel, N. et al. Evaluation of acceptance and perceived barriers to mobile health applications among breast cancer patients and caregivers in a low- to middle-income country. BMC Digit Health 3, 58 (2025). https://doi.org/10.1186/s44247-025-00203-2

o Cazap Eduardo, Anderson Benjamin O, Curigliano Giuseppe, Sehdev Sandeep, Cardoso Fatima, Gonzalez Ana Rita, Shash Emad, Yip Cheng-Har, Mattar André, Chavarri-Guerra Yanin, Mutebi Miriam, Yin Yongmei, Rocha João Victor, Lucibello Ilaria, Srivastava Namita (2025) Bridging gaps in breast cancer care: aBreast Cancer Care Quality Index to improve outcomes worldwide ecancer 19 1981

o Chiu, D.W., Rashad, N., Kordy, N. et al. Epidemiologic and clinical profiles of 

colorectal cancer in Southern Egypt. BMC Gastroenterol 25, 569 (2025). https://doi.org/10.1186/s12876-025-04164-8

o Shash, E., Bektash, F., Montaser, M., Ghobrial, S., Safwat, J., Reda, K., Mahran, N. et al. (2025) ‘Efficacy of a structured educational programme in enhancing breast-cancer knowledge among caregivers in Egypt: a quasi-experimental pilot study’, Clinical Cancer Research, 31(12 Suppl.), Abstract P3-06-11.

o Shash, E., Al Hussini, I.S., Kordy, N., Haggag, A., Seddik, S., Alorabi, M. & Yahia, M. (2025) ‘Oncologists’ prescribing habits for adjuvant therapy in luminal breast cancer: insights from a low-middle-income setting’, Clinical Cancer Research, 31(12 Suppl.), Abstract P3-12-15.

o Shash, E., Kordy, N., Haggag, A., Seddik, S., Al Hussini, I.S., Hashem, T. et al. (2025) ‘Pathologic complete response and residual cancer burden as powerful prognostic markers in HER2-positive early breast cancer: a comprehensive real world study’, Clinical Cancer Research, 31(12 Suppl.), Abstract P3-11-27.

o Shash, E., Bektash, F., Montaser, M., Ghobrial, S., Safwat, J., Reda, K., Mahran, N. & Eid, R. (2025) ‘Efficacy of a structured educational programme in enhancing breast cancer knowledge among caregivers in Egypt: a quasiexperimental pilot study’, Clinical Cancer Research, 31(12 Suppl.), Abstract P3-06-11.

o Bektash, F., Ouda, H.H., Hassan, Y., El-Sayed, A. & Shash, E. (2025) ‘Mapping cancer patient online support groups: enhancing patient care in a low-middleincome healthcare system’, Supportive Care in Cancer, 33(6), 1-8.

o Atherton, J., Gopalakrishnan, S.G., Wahba, Y., Kirollos, R.H., Shash, E., Amin, H.M., El Ghazaly, H.A., Kassem, L., Shohdy, K.S. & Azim, H.A. (2025) ‘280P Key performance indicators of screening via clinical breast examination: a pooled analysis of 9.3 million screened women’, ESMO Open, 10, Abstract 280P.

o Taha, A.M., Kamel, H.A., Khlidj, Y., Salem, D.S., Saed, S.A.A., Abouelmagd, K., Nguyen, D., Shash, E., Chapagain, S. & Kassem, L. (2025) ‘Adjuvant radiotherapy in post-menopausal women with early-stage ER-positive breast cancer: a systematic review and meta-analysis’, Medicine, 104(8), e41632.

o Shash, E., Vardar, M.A., Taskiran, C., Boujassoum, S., Riromar, J., Bahaj, W., Aboutaleb, A. & Sadek, F. (2025) ‘Prevalence of homologous recombination deficiency in ovarian, peritoneal and fallopian-tube cancer in the Middle East’, International Journal of Gynecological Cancer, 35(2), 1-8.

2. 2024

o Shash, E. (2024) ‘Addressing the intersection of chemotherapy-induced peripheral neuropathy and fall risk in cancer survivors: insights and future directions’, JCO Precision Oncology, 8, e2400421.

o El-Shewy, R., Ibrahim, A.H., Mobarez, M.A., Ibrahim, M., Eid, R. & Shash, E. (2024) ‘376P Evaluating adherence to oral anticancer medications in metastatic and non-metastatic breast-cancer patients’, Annals of Oncology, 35(Suppl.), S376–S377.

o Yacoub, E.T.T., Mohammed, M., Abdelaziz, A.H., Shash, E., El-Ghazawy, H., Hussein, N., Amin, H.M. et al. (2024) ‘1558P Independent validation of the Gail model for predicting breast-cancer risk in an Egyptian population’, Annals of Oncology, 35(Suppl.), S946.

o Abdelwhab, Z.M., Adel, N., El-Shewy, R., Eid, R. & Shash, E. (2024) ‘CN19 Evaluation of acceptance and perceived barriers to mobile-health applications among breast-cancer patients and caregivers at the National Cancer Institute, Cairo University’, Annals of Oncology, 35(Suppl.), S1173-S1174.

o Shash, E., Bektash, F., Elhosary, M. et al. (2024) ‘Enhancing patient outcomes through integrated education and navigation programmes at the Breast Cancer Comprehensive Center, National Cancer Institute, Cairo University’, Journal of Cancer Education, 39, advance online publication.

o Shash, E. (2024) ‘Enhancing the impact of digital therapeutics in cancer prevention: reflections on recent findings’, Journal of Cancer Education, 39, advance online publication.

o Mahmoud, A.M.A.S., El Said, N.O., Shash, E. & Ateyya, H. (2024) ‘Prevention of paclitaxel-induced peripheral neuropathy: literature review of potential pharmacological interventions’, Future Journal of Pharmaceutical Sciences, 10(1), 67.

o Korani, O.M., Samy, S.A., Eid, R. & Shash, E. (2024) ‘139P Acceptance to extend hormonal treatment among young Egyptian breast-cancer patients: a crosssectional study’, ESMO Open, 9, 103126.

3. 2023

o Elattar, M., Abdelaziz, A.H., Eshaak, B., Shash, E., El-Zawahery, H., Tawfik, H.et al. (2023) ‘CO92 Clinician-reported outcome measure for palonosetron versus standard of care in chemotherapy-induced nausea and vomiting in Egypt’, Value in Health, 26(12), S31.

o Shash, E., Soliman, G.A., Al-Kharusi, W., Yahia, M., Mwaiselage, J., Mesemo, D. et al. (2023) ‘The value of networking in cancer education and capacity building’, Journal of Cancer Education, 38(6), 1783-1785.

o Elhosary, M., Selim, F., Rostom, J., Mostafa, A., Hammoud, E. & Shash, E. (2023) ‘Guiding towards better care: breast-cancer navigators’ programme implementation for increasing patients’ satisfaction at a comprehensive cancer centre’, The Breast, 71, S36.

4. 2022

o Hamdy, M., Shafik, A., Shash, E. et al. (2022) ‘Egyptian gynecological-oncology experience’, International Journal of Gynecologic Cancer, advance online publication.

o Abusanad, A.M., Bensalem, A., Shash, E., Mula-Hussain, L.Y.I., Benbrahim, Z., Khatib, S. et al. (2022) ‘Prevalence and risk factors of burnout among female oncologists from the Middle East and North Africa’, Frontiers in Psychology, 13, 845024.

o Rashad, N., Abdulla, M., Farouk, M., Elkerm, Y., Salem, S.E., Yahia, M. et al.(2022) ‘Resource-oriented decision-making for treatment of metastatic colorectal cancer in a lower-middle-income country: EFMS consensus recommendations 2020’, Cancer Management and Research, 14, 821-842.

5. 2021

o El Bairi, K., Haynes, H.R., Blackley, E., Fineberg, S., Shear, J., Turner, S. et al.(2021) ‘The tale of TILs in breast cancer: a report from the International ImmunoOncology Biomarker Working Group’, npj Breast Cancer, 7, 150.

o Abusanad, A., Bensalem, A., Shash, E., Mula-Hussain, L.Y.I., Benbrahim, Z., Khatib, S.A. et al. (2021) ‘11016 Burnout among oncology professionals in the Middle East and North Africa (MENA)’, Journal of Clinical Oncology, 39(15 Suppl.), 11016.6. 2020

o Shash, E., Khorshed, E., Namour, A., El Desouky, E., Bahnassy, A. & Allahloubi, N.M.A. (2020) ‘Clinical correlation between PD-L1 expression, tumourinfiltrating lymphocytes and pathological response of locally advanced HER2-positive and triple-negative breast-cancer patients undergoing neoadjuvant therapy’, European Journal of Cancer, 138(Suppl. 1), S73.

o Abusanad, A.M., Bensalem, A., Shash, E., Mula-Hussain, L.Y.I., Benbrahim, Z., Khatib, S.A. et al. (2020) ‘Burnout among oncology professionals in the Middle East and North Africa’, Psycho-Oncology, 29(8), 1412-1420.7. 2018-2010

o Elsebaie, M.A.T., Amgad, M., Elkashash, A., Elgebaly, A.S., Shash, E. & Elsayed, Z. (2018) ‘Management of low- and intermediate-risk adult rhabdomyosarcoma: a pooled survival analysis of 553 patients’, Scientific Reports, 8, 9337.

o Bagot, M., Hasan, B., Whittaker, S. et al. (2017) ‘A phase III study of lenalidomide maintenance after debulking therapy in advanced cutaneous T-cell lymphoma’, European Journal of Dermatology, 27(3), 286-294.

o Shash, E. (2017) ‘Editor’s perspective: how rare is rare?’, Journal of the Egyptian National Cancer Institute, 29(2), 67.

o van der Steen-Banasik, E., Christiaens, M., Shash, E. et al. (2016) ‘Radiation therapy alone in medically non-operable endometrial carcinoma: a systematic review’, European Journal of Cancer, 65, 172-181.

o Bolla, M., Maingon, P., Carrie, C. et al. (2016) ‘Short androgen suppression and radiation-dose escalation for intermediate- and high-risk localised prostate cancer: results of EORTC 22991’, Journal of Clinical Oncology, 34(15), 1748-1756.

o Shash, E. (2016) ‘Tenosynovial giant-cell tumour: better molecular understanding revolutionises treatment outcome’, Advances in Modern Oncology Research, 2(1), 2-4.

o Amgad, M. & Shash, E. (2015) ‘The evolution of undergraduate medical-student research activities: experience of a developing nation’s uprise’, Journal of CancerEducation, 30(4), 813-814.

o Adebahr, S., Collette, S., Shash, E. et al. (2015) ‘In reply to Dahele et al.: stereotactic body radiotherapy for central lung tumours’, British Journal of Radiology, 88, 20150532.

o Amgad, M., Tsui, M.M.K., Liptrott, S.J. & Shash, E. (2015) ‘Medical-student research: a mixed-methods systematic review and meta-analysis’, PLOS ONE, 10(6), e0127470.

o Adebahr, S., Collette, S., Shash, E. et al. (2015) ‘LungTech: an EORTC phase II trial of stereotactic body radiotherapy for centrally located lung tumours—a clinical perspective’, British Journal of Radiology, 88(1051), 20150036.

o Shash, E., Vergote, I., Boere, I., Casado, A. & Coens, C. (2014) ‘Phase I study of pazopanib with weekly paclitaxel and carboplatin in platinum-resistant ovarian carcinoma’, International Journal of Gynecologic Cancer, 24(9 Suppl. 4), 475-476.

o Joly, F., McAlpine, J., Nout, R. et al. (2014) ‘Quality of life and patient-reported outcomes in endometrial-cancer trials: a call for action’, International Journal of Gynecologic Cancer, 24(9), 1693-1699.

o McAlpine, J.N., Greimel, E., Brotto, L.A. et al. (2014) ‘Quality-of-life research in endometrial cancer: methodological considerations’, International Journal of Gynecologic Cancer, 24(9), 1686-1692.

o Maingon, P., Govaerts, A-S., Rivera, S., Vens, C., Shash, E. & Vincent, G. (2014) ‘New challenge of developing combined radio-drug therapy’, Translational Cancer Research, 3(2), 1-7.

o Shash, E. (2014) ‘An example of the integrated model: the EORTC DAHANCA-1219 trial’, Radiotherapy and Oncology, 110(Suppl. 1), S40.

o Shash, E. (2014) ‘The new business model of the European Organisation for Research and Treatment of Cancer’, Radiotherapy and Oncology, 110(Suppl. 1), S89.

o Rivera, S., Vens, C., Maingon, P., Govaerts, A-S., Shash, E. et al. (2013) ‘Combining novel targeted therapies and radiotherapy: a challenge to overcome’, Molecular Cancer Therapeutics, 12(11 Suppl.), C220.

o Casado, A., Shash, E. & Ottevanger, N. (2013) ‘The role of EORTC-GCG in the current European research landscape’, International Journal of Gynecologic Cancer, 23(8 Suppl. 1), 209.

o Shash, E., Negrouk, A., Marreaud, S. et al. (2013) ‘International clinical-trial setting for rare cancers: the EORTC perspective’, ecancermedicalscience, 7, 321.

o Whittaker, S., Ortiz-Romero, P.L., Dummer, R. et al. (2012) ‘Efficacy and safety of bexarotene with PUVA versus PUVA alone in stage IB-IIa mycosis fungoides’,Journal of Clinical Oncology, 30(15 Suppl.), Abstract 8076.

o Gaafar, R., Shash, E. & El-Haddad, A. (2012) ‘Cancer education for medical students in developing countries: where do we stand?’, Critical Reviews in Oncology/Hematology, 84(1), 122-129.

o Shash, E., Bassi, S., Cocorocchio, E., Colpi, G.M., Cinieri, S. & Peccatori, F.A. (2011) ‘Fatherhood during imatinib’, Acta Oncologica, 50(5), 734-735.

o Khorshid, O., Baradie, M., Ismail, H. et al. (2011) ‘Male breast cancer: clinic. pathological data and impact on survival’, Annals of Oncology, 22(Suppl. 2), ii60-

ii64.

o Shash, E. & Peccatori, F.A. (2011) ‘Optimising the use of EGFR inhibitors in advanced non-small-cell lung cancer’, Journal of Thoracic Disease, 3(1), 57-64.

o Gaafar, R., Shash, E., El-Haddad, A. & Abdel Hady, S. (2011) ‘Teaching oncology to medical students is a must: the Egyptian NCI step on the road’, Journal of Cancer Education, 26(3), 547-548.

o Abdulla, M. & Shash, E. (2011) Sunitinib efficacy in advanced pancreatic neuroendocrine tumours’, Clinical Medicine Reviews in Oncology, 3, 1-7.